首页|心力衰竭患者利尿剂抵抗的发病机制与治疗进展

心力衰竭患者利尿剂抵抗的发病机制与治疗进展

扫码查看
心力衰竭(HF)是各种原发或继发性心脏病的最终结局,是全世界的重大健康问题之一。控制钠摄入及使用利尿剂被普遍认为是HF的基本治疗方式,但有20%~50%的心力衰竭患者存在利尿剂抵抗(DR)。DR与HF患者心血管事件的风险增加、住院时间延长以及再入院有关。现概述HF患者中的DR现象,并全面总结其发病机制及治疗,旨在为临床医生及科研人员提供更全面、多维度的理解,促进对合并DR的HF患者的发病机制和治疗策略的深入探讨。
Pathogenesis and Treatment of Diuretic Resistance in Patients with Heart Failure
Heart failure(HF)is the ultimate outcome of various primary or secondary cardiac diseases and stands as a significant global health concern.Controlling sodium intake and using diuretics are widely recognized as fundamental therapeutic approaches for HF.However,approximately 20%to 50%of HF patients experience diuretic resistance(DR).DR is associated with an increased risk of cardiovascular events,prolonged hospitalization,and readmission in HF patients.This review aims to outline the phenomenon of DR in HF patients,comprehensively summarizing its pathogenesis and treatment.It is intended to provide clinicians and researchers with a more comprehensive and multidimensional understanding,promoting in-depth discussions on the pathogenesis and treatment strategies for HF patients with DR.

Heart failureDiureticDiuretic resistance

李忠衡、李睿宁、叶桢、刘艺硕、孙丽杰

展开 >

北京大学第三医院北京大学第三医院心内科卫生部心血管分子生物学与调节肽重点实验室,北京 100191

北京大学医学部,北京 100191

心力衰竭 利尿剂 利尿剂抵抗

北京市慢性病防治与健康教育科研项目

BJMB0012021025009

2024

心血管病学进展
成都市心血管病研究所,成都市第三人民医院

心血管病学进展

CSTPCD
影响因子:0.932
ISSN:1004-3934
年,卷(期):2024.45(8)